Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer

World Journal of Urology

Volumn 31, Issue 6, 2013, Pages 1327-1332

  Hardie, Andrew D ^a   Rieter, William J ^a   Bradshaw, Marques L ^a   Gordon, Leonie L ^a   Young, Matthew A ^a   Keane, Thomas E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Diffusion weighted MRI; In 111 capromab pendetide; Lymph nodes; Prostate cancer

Indexed keywords

CAPROMAB PENDETIDE IN 111; DIAGNOSTIC AGENT; INDIUM; MONOCLONAL ANTIBODY;

AGED; ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; EVALUATION STUDY; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PELVIS TUMOR; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; RADIOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; ANTIBODIES, MONOCLONAL; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; INDIUM RADIOISOTOPES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PELVIC NEOPLASMS; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84888287227     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1079-2     Document Type: Article

References (26)

1. Gervasi LA, Mata J, Easley JD et al (1989) Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 142(2 Pt 1): 332-336.
2. Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167(4): 1681-1686.
3. Briganti A, Larcher A, Abdollah F et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61(3): 480-487.
4. Briganti A, Blute ML, Eastham JH et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55(6): 1251-1265.
5. Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni NM, Salonia A, Colombo R, Freschi M, Rigatti P, Montorsi F (2012) Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol 61(6): 1132-1138 Epub 2011 Nov 12.
6. Hovels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4): 387-395.
7. Bander NH (2006) Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3: 216-225.
8. Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7: 927-935.
9. Troyer JK, Beckett ML, Wright GL (1997) Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30: 232-242.
10. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3: 81-85.
11. Wright GL Jr, Grob BM, Haley C et al (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48: 326-334.
12. Sweat SD, Pacelli A, Murphy GP, Bostwick DG (1998) Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52: 637-640.
13. Wynant GE, Murphy GP, Horoszewicz JS et al (1991) Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5. 3 (CYT-356). Prostate 18: 229-241.
14. Manyak MJ, Hinkle GH, Olsen JO et al (1999) Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 54: 1058-1063.
15. Schettino CJ, Kramer EL, Noz ME, Taneja S, Padmanabhan P, Lepor H (2004) Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. Am J Roentgenol 183: 519-524.
16. Rieter WJ, Keane TE, Ahlman MA, Ellis CT, Spicer KM, Gordon LL (2011) Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer. Clin Nucl Med 36(10): 872-878.
17. Wesbey GE, Moseley ME, Ehman RL (1984) Translational molecular self-diffusion in magnetic resonance imaging. II. Measurement of the self-diffusion coefficient. Invest Radiol 19(6): 491-498.
18. Abdel Razek AA, Soliman NY, Elkhamary S, Alsharaway MK, Tawfik A (2006) Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 16(7): 1468-1477.
19. Holzapfel K, Duetsch S, Fauser C, Eiber M, Rummeny EJ, Gaa J (2009) Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol 72(3): 381-387.
20. Sumi M, Sakihama N, Sumi T et al (2003) Discrimination of metastatic cervical lymph nodes with diffusion-weighted MR imaging in patients with head and neck cancer. AJNR Am J Neuroradiol 24(8): 1627-1634.
21. King AD, Ahuja AT, Yeung DK et al (2007) Malignant cervical lymphadenopathy: diagnostic accuracy of diffusion-weighted MR imaging. Radiology 245(3): 806-813.
22. Kim JK, Kim KA, Park BW, Kim N, Cho KS (2008) Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. J Magn Reson Imaging 28(3): 714-719.
23. Thoeny HC, Triantafyllou M, Birkhaeuser FD et al (2009) Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 55(4): 761-769.
24. Beer AJ, Eiber M, Souvatzoglou M et al (2011) Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol 13(2): 352-361.
25. Budiharto T, Joniau S, Lerut E et al (2011) Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 60(1): 125-130.
26. Mattei A, Danuser H (2011) Contemporary imaging analyses of pelvic lymph nodes in the prostate cancer patient. Curr Opin Urol 21(3): 211-218.